NSRX - Nasus Pharma Ltd.
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $26.0M
- Beta
- 3.89
- 52-Week Range
- 1.98-9.99
- CEO
- Dan Teleman
- Employees
- 2
- IPO Date
- Aug 13, 2025
- Exchange
- AMEX
NSRX Options Snapshot
Options pricing data for NSRX is refreshed daily after the close. When listed contracts exist, this page surfaces the latest at-the-money implied volatility, max pain strike, dealer gamma exposure (GEX), and 25-delta skew. Listed contracts and live snapshots appear once the options chain has been published by the exchange for the most recent session.
What This Page Covers
The NSRX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked NSRX overview questions
- What is NSRX?
- NSRX is the ticker symbol for Nasus Pharma Ltd., a listed security. Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. Listed on AMEX. NSRX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What are NSRX's key statistics?
- Nasus Pharma Ltd. (NSRX) carries a market capitalization of $26.0M, beta of 3.89 relative to the broader market, 52-week range of 1.98-9.99. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does NSRX belong to?
- Nasus Pharma Ltd. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare NSRX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the NSRX data on this page?
- Options snapshots refresh after each trading session; if no snapshot is currently posted for NSRX, it usually reflects low options liquidity or a recently listed name. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).